ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.505,70
0,47%
S&P 500
6.027,99
0,56%
Dow Jones
44.476,05
0,12%
Euro vs US Dollar
1,03857
0,56%
Bitcoin
99.460,58
-1,93%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Ultragenyx Pharmaceutical Inc (RARE) Börsenkurse

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc (RARE)

ETF
Tactical Resources Corp
Wt Etmtl & Rare
WisdomTree Issuer ICAV
Tactical Resources Corp
WisdomTree Japan Equity UCITS ETF USD Acc
44,2533
0,8333
( 1,92% )
Aktualisiert: 19:42:30
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
44,2533
Gebot
44,20
Fragen
44,25
Volumen
153.689
43,23 Tagesbereich 44,5299
37,02 52-Wochen-Bereich 60,37
Marktkapitalisierung
4,087B
Handelsende
43,42
Handelsbeginn
43,23
Letzte Trade
50
@
44.2651
Letzter Handelszeitpunkt
19:43:38
Finanzvolumen
US$ 6.751.951
VWAP
43,9326
Durchschnittliches Volumen (3 Mio.)
817.559
Ausgegebene Aktien
92.344.268
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-6,72
Gewinn pro Aktie (EPS)
-6,57
Erlöse
434,25M
Nettogewinn
-606,64M

Über Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Cr... Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.ultragenyx.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RARE. The last closing price for Ultragenyx Pharmaceutical was US$43,42. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 37,02 to US$ 60,37.

Ultragenyx Pharmaceutical currently has 92.344.268 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$4,01 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -6.72.

RARE Neueste Nachrichten

Weitere Nachrichten

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

17 Januar 2025
GlobeNewswire Inc.

Form 8-K - Current report

13 Januar 2025
Edgar (US Regulatory)

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to...

12 Januar 2025
GlobeNewswire Inc.

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

06 Januar 2025
GlobeNewswire Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

20 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

19 Dezember 2024
Edgar (US Regulatory)

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study...

19 Dezember 2024
GlobeNewswire Inc.

Form 8-K - Current report

19 Dezember 2024
Edgar (US Regulatory)

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...

19 Dezember 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

12 Dezember 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.88332.036661286643.3744.529941.8952107443.0061115CS
41.14332.6520528879643.1146.2439.7985235542.40914611CS
12-6.0267-11.986276849650.2850.4839.7981755944.25183213CS
26-2.7067-5.7638415672946.9660.3739.7975813949.39670332CS
521.63333.8322383857342.6260.3737.0277857146.80565038CS
156-23.1167-34.313047350567.3785.5331.5271768846.08573072CS
260-10.2567-18.816180517354.51179.64731.5261861260.15506553CS

RARE - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?
The current share price of Ultragenyx Pharmaceutical is US$ 44,2533
How many Ultragenyx Pharmaceutical shares are in issue?
Ultragenyx Pharmaceutical has 92.344.268 shares in issue
What is the market cap of Ultragenyx Pharmaceutical?
The market capitalisation of Ultragenyx Pharmaceutical is USD 4,01B
What is the 1 year trading range for Ultragenyx Pharmaceutical share price?
Ultragenyx Pharmaceutical has traded in the range of US$ 37,02 to US$ 60,37 during the past year
What is the PE ratio of Ultragenyx Pharmaceutical?
The price to earnings ratio of Ultragenyx Pharmaceutical is -6,72
What is the cash to sales ratio of Ultragenyx Pharmaceutical?
The cash to sales ratio of Ultragenyx Pharmaceutical is 9,38
What is the reporting currency for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical reports financial results in USD
What is the latest annual turnover for Ultragenyx Pharmaceutical?
The latest annual turnover of Ultragenyx Pharmaceutical is USD 434,25M
What is the latest annual profit for Ultragenyx Pharmaceutical?
The latest annual profit of Ultragenyx Pharmaceutical is USD -606,64M
What is the registered address of Ultragenyx Pharmaceutical?
The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Ultragenyx Pharmaceutical website address?
The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com
Which industry sector does Ultragenyx Pharmaceutical operate in?
Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
CAPTCaptiVision Inc
US$ 1,13
(157,40%)
209,97M
QNTMQuantum Biopharma Ltd
US$ 5,33
(67,61%)
49,9M
NVVENuvve Holding Corporation
US$ 4,36
(64,53%)
10,86M
LTRYLottery com Inc
US$ 0,4771
(52,92%)
95,81M
LXEHLixiang Education Holding Company Ltd
US$ 7,79
(44,26%)
290,03k
OMGAOmega Therapeutics Inc
US$ 0,1954
(-59,22%)
4,8M
TOIIWOncology Institute Inc
US$ 0,021
(-46,43%)
171
VIRXViracta Therapeutics Inc
US$ 0,0505
(-35,09%)
4,27M
UPCUniverse Pharmaceuticals Inc
US$ 0,2783
(-33,33%)
1,37M
CYNCYNGN Inc
US$ 0,0806
(-31,05%)
69,11M
CAPTCaptiVision Inc
US$ 1,13
(157,40%)
209,97M
PLTRPalantir Technologies Inc
US$ 102,55
(22,46%)
180,35M
NVDANVIDIA Corporation
US$ 119,37
(2,32%)
162,51M
RGTIRigetti Computing Inc
US$ 13,745
(2,04%)
131,15M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,1581
(-18,88%)
100,43M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
RARE
Ultragenyx Pharmaceutical
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten